FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)

Osteoporosis Clinical Trial

Official title:

Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of FOSAMAX PLUS and FOSAMAX PLUS D in Usual Practice

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01065779
• Other study ID #: 0217A-267
• Secondary ID: 2010_007
• Status: Completed
• Start date: March 2006
• Est. completion date: July 2010

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS D through collecting the safety information according to the Re-examination Regulation for New Drugs.

Note: FOSAMAX PLUS D is known as FOSAMAX PLUS in several markets. FOSAMAX PLUS (70 mg/2800 IU) and FOSAMAX PLUS D (70 mg/5600 IU).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 880
• Est. completion date: July 2010
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants who are treated with FOSAMAX PLUS / FOSAMAX PLUS D within label for the first time

Exclusion Criteria:

• Participants who have a contraindication to FOSAMAX PLUS / FOSAMAX PLUS D according to the current local label

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Drug:
• FOSAMAX PLUS
Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
• FOSAMAX PLUS D
Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Serious Adverse Events	Number of participants that experienced Serious Adverse events (SAE). There was no required routine visit scheduled for AE assessment. AEs were collected through participant self-reporting and assessed by investigators.; SAEs were considered serious if the event resulted in: death or was life-threatening; prolonged an existing inpatient hospitalization; a persistent or significant disability/ incapacity; a congenital anomaly/ birth defect; a significant medical situation, other important medical event based upon appropriate medical judgment of the investigator	Up to ~ 16 weeks and 14 days after treatment discontinuation
Primary	Number of Participants With Unexpected Adverse Events	Number of participants that experienced unexpected Adverse Events (AEs) regardless of whether or not the AE was considered related to the use of the product. There was no required routine visit scheduled for AE assessment. An AE was defined as any unfavorable & unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the product, was also considered an AE.	Up to ~ 16 weeks and 14 days after treatment discontinuation
Primary	Number of Participants With Non-Serious AEs	An AE was defined as any unfavorable & unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the product, was also considered an AE. There was no required routine visit scheduled for AE assessment. AEs were collected through participant self-reporting and assessed by investigators.	Up to ~ 16 weeks and 14 days after treatment discontinuation
Primary	Number of Participants With Improved, Unchanged, or Worsened Disease	Evaluation of disease improvement was conducted in 3 categories of "improved", "unchanged", or "worsened". Changes in biochemical markers and vitamin D levels were reviewed before (baseline) and after treatment using statistical analyses to determine disease status, which was reported as either "improved", "unchanged", or "worsened".	Baseline and end of Treatment (Up to ~ 16 weeks)
Primary	Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment	For efficacy evaluation, changes in Serum 25-hydroxyvitamin D were evaluated before study drug administration and at end of study drug treatment. Change was calculated as the later time point (at ~16 weeks) minus the earlier time point (baseline). The Last Observation Carried Forward (LOCF) method was used. That is, the last observed non-missing value was used to fill in missing values at the later point in the study.	Baseline and End of Treatment (Up to ~ 16 weeks)
Primary	Change From Baseline in Serum Osteocalcin at End of Treatment	For efficacy evaluation, changes in Serum Osteocalcin were evaluated before study drug administration and at end of study drug treatment. Change was calculated as the later time point (at ~16 weeks) minus the earlier time point (baseline). The Last Observation Carried Forward (LOCF) method was used. That is, the last observed non-missing value was used to fill in missing values at the later point in the study.	Baseline and End of Treatment (Up to ~ 16 weeks)
Primary	Change From Baseline in Urine Deoxypyridinoline at End of Treatment	For efficacy evaluation, changes in Serum Deoxypyridinoline were evaluated before study drug administration and at end of study drug treatment. Change was calculated as the later time point (at ~16 weeks) minus the earlier time point (baseline). The Last Observation Carried Forward (LOCF) method was used. That is, the last observed non-missing value was used to fill in missing values at the later point in the study.	Baseline and End of Treatment (Up to ~ 16 weeks)
Primary	Change From Baseline in Alkaline Phosphatase at End of Treatment	For efficacy evaluation, changes in Serum Alkaline Phosphatase were evaluated before study drug administration and at end of study drug treatment. Change was calculated as the later time point (at ~16 weeks) minus the earlier time point (baseline). The Last Observation Carried Forward (LOCF) method was used. That is, the last observed non-missing value was used to fill in missing values at the later point in the study.	Baseline and End of Treatment (Up to ~ 16 weeks)